ZNTL
NASDAQ · Biotechnology
Zentalis Pharmaceuticals Inc
$2.60
-0.10 (-3.70%)
Financial Highlights (FY 2026)
Revenue
72.61M
Net Income
-178,578,310
Gross Margin
—
Profit Margin
-246.0%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 54.6% | 54.6% | 54.6% |
| Operating Margin | -283.6% | -8.2% | -7.5% | -8.0% |
| Profit Margin | -246.0% | -8.1% | -6.1% | -7.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 72.61M | 27.61M | 25.42M | 27.85M |
| Gross Profit | — | 15.07M | 13.87M | 15.20M |
| Operating Income | -205,891,661 | -2,265,034 | -1,909,179 | -2,222,029 |
| Net Income | -178,578,310 | -2,223,610 | -1,538,415 | -1,953,169 |
| Gross Margin | — | 54.6% | 54.6% | 54.6% |
| Operating Margin | -283.6% | -8.2% | -7.5% | -8.0% |
| Profit Margin | -246.0% | -8.1% | -6.1% | -7.0% |
| Rev Growth | — | +21.3% | +16.0% | +14.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 11.52M | 10.77M | 11.77M |
| Total Equity | — | 88.47M | 80.04M | 88.96M |
| D/E Ratio | — | 0.13 | 0.13 | 0.13 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -204,495,165 | -3,072,165 | -2,609,903 | -3,215,308 |
| Free Cash Flow | — | -1,433,660 | -1,157,693 | -1,340,683 |